SCHEMBL7685833

SCHEMBL7685833

CCOC(=O)c1c(C)nc(-c2ccccc2)c(C(=O)OCC)c1C=O

nearest known ligand 0.76

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 11/20 0.76
ALDH1A1 P00352 5/20 0.60
LMNA P02545 4/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
KDM4E B2RXH2 3/20 0.60
MAPT P10636 3/20 0.60
RAB9A P51151 2/20 0.60
NPC1 O15118 2/20 0.60
GAA P10253 1/20 0.60
HPGD P15428 1/20 0.60
NPSR1 Q6W5P4 1/20 0.60
TP53 P04637 1/20 0.54
HSD17B10 Q99714 1/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
TSHR P16473 2/20 0.50
MAPK1 P28482 1/20 0.48
ATM Q13315 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7678825 0.81 ADORA3 (1.00) ADORA3ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL13780197 0.81 ADORA3 (0.74) ADORA3ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL27708854 0.79 ADORA3 (0.67) ADORA3ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL7686715 0.79 ADORA3 (0.90) ADORA3ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL7686721 0.78 ADORA3 (1.00) ADORA3ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL7678610 0.77 ADORA3 (0.68) ADORA3ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL28199488 0.76 ADORA3 (0.76) ADORA3ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL3703552 0.76 ADORA3 (0.87) ADORA3ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL15976546 0.76 ALDH1A1 (1.00) ADORA3ALDH1A1LMNASMN1; SMN2KDM4E
SCHEMBL10073336 0.76 KDM4E (0.81) ADORA3ALDH1A1LMNASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6376521-B1 ANTIINFLAMMATORY AGENTS; ANTIISCHEMIC AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2002-04-23 US disclosed